# 1 Using electronic health records to evaluate the adherence to cervical cancer

# 2 prevention guidelines: a cross-sectional study

- 3 Kerli Mooses\*<sup>1</sup>, Aleksandra Šavrova<sup>2</sup>, Maarja Pajusalu<sup>1</sup>, Marek Oja<sup>1</sup>, Sirli Tamm<sup>1</sup>, Markus
- 4 Haug<sup>1</sup>, Lee Padrik<sup>3</sup>, Made Laanpere<sup>3,4</sup>, Anneli Uusküla<sup>5</sup>, Raivo Kolde<sup>1</sup>

# 5

- 6 <sup>1</sup> Institute of Computer Science, University of Tartu, Tartu, Estonia
- 7 <sup>2</sup> North Estonia Medical Center, Tallinn, Estonia
- 8 <sup>3</sup> Tartu University Hospital Women's Clinic, Tartu, Estonia
- 9 <sup>4</sup> Institute of Clinical Medicine, University of Tartu, Tartu, Estonia
- <sup>5</sup> Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia

11

# 12 Corresponding author:

- 13 Kerli Mooses,
- 14 Aadress: Narva mnt 18, Tartu, Tartumaa, 51009, Estonia
- 15 Phone: +372 5526542
- 16 E-mail: <u>Kerli.mooses@ut.ee</u>

#### 18 ABSTRACT

19 **Objective:** The fight against cervical cancer requires effective screening together with optimal 20 and on-time treatment along the care continuum. We aimed to examine the impact of cervical 21 cancer screening and treatment guidelines on screening, and follow-up adherence to guidelines. 22 Methods: Data from electronic health records and healthcare provision claims for 50 702 23 women was used. The annual rates of PAP tests, HPV tests and colposcopies during two 24 guideline periods (2nd version 2012-2014 vs 3rd version 2016-2019) were compared. To 25 assess the adherence to guidelines, the subjects were classified as adherent, over- or undertested 26 based on the timing of the appropriate follow-up test.

27 Results: The number of PAP tests decreased and HPV tests increased during the 3rd guideline 28 period (p < 0.01). During the 3rd guideline period, among 21–29-year-old women, the 29 adherence to guidelines ranged from 38.7% (44.4...50.1) for ASC-US to 73.4% (62.6...84.3) 30 for HSIL, and among 30-59-year-old from 49.0% (45.9...52.2) for ASC-US to 65.7% 31 (58.8...72.7) for ASC-H. The highest rate of undertested women was for ASC-US (21-29y: 32 25.7%; 30–59y: 21.9%). The rates of over-tested women remained below 12% for all cervical pathologies observed. There were 55.2% (95% CI 49.7...60.8) of 21-24-year-old and 57.1% 33 34 (95% CI 53.6...60.6) of 25-29-year-old women who received an HPV test not adherent to the guidelines. 35

36 **Conclusions**: Our findings highlighted some shortcomings in the adherence to guidelines, 37 especially among women under 30. The insights gained from this study helps to improve the 38 quality of care and thus, reduce cervical cancer incidence and mortality.

39

40 Keywords: cervical cancer, guideline adherence, undertesting, over-testing, optimal care, early

41 detection of cancer, electronic health records, healthcare claims

42 Word count: Abstract: 250 words ; Manuscript: 3104 words

### 43 INTRODUCTION

44 Cervical cancer, one of the most common malignant neoplasms among women [1], is 45 preventable with the timely discovery of pre-cancerous lesions and appropriate treatment [2]. 46 Moreover, World Health Organisation has set a target to eliminate cervical cancer as a public 47 health problem [2]. To fulfil this goal, countries have developed their own national guidelines 48 for screening and management of cervical abnormalities, while others adhere to only 49 international ones [8,9]. These guidelines have changed over time together with the evolution 50 of scientific knowledge [3] and try to offer the best protection against cervical cancer while 51 balancing the benefits and harms of the testing and ensuring the effective use of healthcare 52 resources. Therefore, it is crucial that these guidelines are followed and effectively 53 implemented in the practice. Despite this, both underscreening and over-screening has been 54 reported [4–8]. For example, underscreening has remained a challenge in several countries as 55 the adherence to screening guidelines in developed countries is on average 63% [4], ranging 56 from 37% to 82% in Europe [5]. At the same time, a considerable amount of women are tested 57 more often than recommended [6,7,9]. Too frequent testing is not only a financial burden to 58 the healthcare system but can lead to overtreatment and have a negative impact on the 59 reproductive health [10]. While several studies have found difficulties in adopting new 60 guidelines in the US and thus, causing the increase in over-testing [6,7,9], there is a lack of 61 similar studies in Europe.

To assure screening benefits, it is crucial to involve and maintain women from screening to treatment and to follow-up along a care continuum. It has been estimated that 12% of invasive cervical cancer cases are attributable to poor follow-up after abnormal PAP test [11]. To date, the data about treatment and follow-up patterns is limited and the need for additional studies has been stressed [12,13]. There are some studies describing the follow-up of abnormal screening results, however, in most cases, the focus is on the timing of the follow-up test [12,14–16], while less attention has been paid to the additional tests [13]. More detailed
information about the treatment pathways help to provide better treatment and care for women
and reduce the incidence of cervical cancer.

Previously, it has been highlighted that there is a considerable amount of research that fails to 71 72 improve practice as it does not address questions that are important to practitioners, it is not 73 applicable to real-life, patient-centred or available to policy makers [17–20]. To increase the 74 practicability of current study and to ensure that the results are disseminated and implemented 75 into the practice, it has been conducted in close co-operation with Estonian Gynaecologists 76 Society and several practitioners. Moreover, to get better overview of the real situation we 77 incorporated diverse types of real-world data. Thus, in the current study, we utilized nationwide 78 and population-based electronic health record (EHR) and healthcare provision claims data with 79 the aim to investigate the influence of cervical cancer screening guidelines on testing practices, 80 and the adherence to guidelines in the case of follow-up tests.

81

## 82 MATERIAL AND METHODS

#### 83 Setting

84 In Estonia, the evidence-based guideline for diagnosing, monitoring, and treatment of precancerous cervical, vaginal, and vulvar conditions is developed and disseminated by the 85 Estonian Gynaecologists Society. In the current cross-sectional study, we focus on the 2<sup>nd</sup> 86 (2007–2014) and 3<sup>rd</sup> (2014–2021) versions of the guidelines. During the 2<sup>nd</sup> version the primary 87 88 screening test was the PAP test with a one-year interval between the first two tests, which in case of no abnormalities, was followed by a two-year testing interval. The 3<sup>rd</sup> version of the 89 guideline recommended a three-year testing interval with a PAP test or a five-year interval 90 91 when HPV or co-testing was applied.

### 93 Data

94 In this cross-sectional study we combined data from two health databases with national 95 coverage - EHR and healthcare service provision claims from 01.01.2012 to 31.12.2019. The databases were linked using a unique personal code given to all persons living in Estonia. The 96 97 data was transferred to Observational Medical Outcomes Partnership (OMOP) common data 98 model (CDM) version 5.3 [22] described in more detail by Oja et al [23]. The study sample 99 consisted of randomly selected 10% of the Estonian female population aged 16–65 years (N = 100 50 702) and followed the age distribution of the whole female population [23]. The study was 101 approved by the Research Ethics Committee of the University of Tartu (300/T-23) and the 102 Estonian Committee on Bioethics and Human Research (1.1-12/653) and the requirement for 103 informed consent was waived.

104 The episodes of cervical cytology together with diagnoses, HPV tests and colposcopies were 105 identified from EHR and claims databases. When one PAP test had multiple diagnoses (eg 106 NILM and LSIL), the most severe pathology was used. Cervical cytology results were 107 categorised according to the Bethesda system criteria: [24] negative for intraepithelial lesion or 108 malignancy (NILM); atypical squamous cells of undetermined significance (ASC-US); low-109 grade squamous intraepithelial lesions (LSIL); atypical squamous cells cannot exclude high-110 grade squamous intraepithelial lesions (ASC-H); high-grade squamous intraepithelial lesions 111 (HSIL). The corresponding Standard Nomenclature of Medicine (SNOMED) codes are 112 presented in Table S1.

113

# 114 Assessing the effect of guidelines on the testing practices

The data about all PAP tests, HPV tests and colposcopies during 2012–2014 (2<sup>nd</sup> version) were compared with data from 2016–2019 (3<sup>rd</sup> version). The year 2015 was considered a transition period and was left out from the comparison. In this analysis, we present the annual testing rates for the target group of the guidelines (21–65-year-old women) and the younger age group
(16–20-year-old) who should not receive any testing.

120

# 121 Assessing the adherence to cervical cancer prevention and care continuum

122 Follow-up of PAP tests

We described the follow-up during the 3<sup>rd</sup> guideline version (2015–2019) when the PAP result 123 was NILM, ASC-US, LSIL, ASC-H, or HSIL. For each PAP test result under observation a 124 125 separate cohort was created with similar inclusion criteria: 1) the first corresponding PAP test 126 result was recorded after 01.01.2015 (index event), 2) there was no occurrence of more serious 127 cervical pathology 30 days before and after the index date, 3) no previous diagnosis of the same 128 cervical pathology within three years before the index event was present (not applicable to 129 NILM), 4) a follow-up period after the index date was at least 15 months for cervical 130 pathologies and 3.5 years for NILM. Women with a history of HIV, cervical cancer or 131 hysterectomy were excluded from the analysis. When describing the follow-up of NILM we 132 also excluded women whose PAP test was accompanied by an HPV test, as in the case of co-133 testing, the recommended testing interval was longer (five years). In this analysis we focused 134 on two age groups: 21–29 and 30–59-year-olds.

135 In Table 1 we present the follow-up tests after NILM and cervical pathologies according to the 136 guidelines together with the adherence and undertested criteria deployed in the analysis. The 137 adherence to guidelines was assessed in terms of timing and appropriate follow-up test. When 138 the appropriate follow-up test was performed in a time interval specified in the guidelines and 139 no additional test was present, the woman was considered as adherent. To provide some 140 flexibility and account for possible shifts caused by appointment scheduling, we allowed a time 141 lag when classifying the test as adherent. For example, according to the guidelines in the case 142 of NILM the follow-up PAP test should be done after three years, however, when the next PAP

test was done two years and seven months or three years and four months after the index date, it was considered adherent. Those women who had a follow-up test according to the guidelines but in addition had some PAP or HPV test(s) between the index test and an adherent follow-up test, were classified as over-tested, while women who did not receive any test after the PAP test, were classified as undertested. Women who did not belong to adherent, over- or undertested group were left out from current analysis (n = 2997, 32.5%).

149

150 **Table 1.** The follow-up tests of NILM and cervical abnormalities according to the guidelines

151 and the adherence definition in the analysis.

	Age	Guidelines	Adherent in the analysis*	Undertested in the analysis	
NILM	21–59	New PAP test after 3 years	New PAP test between 2.5 to 3.5	No test within 3.5 years	
			years		
ASC-US	21–59	New PAP test after 12 months	New PAP test between 9–15 months	No test within 15 months	
		OR	OR		
		Immediate HPV test	HPV test in 3 months		
LSIL	21–24	New PAP test after 12 months	New PAP test between 9–15 months		
	25–59	New PAP test after 12 months	Co-test between 9–15 months	No test within 15 months	
		OR			
		Immediate colposcopy	Colposcopy in 3 months		
ASC-H	21–59	Colposcopy	Colposcopy in 3 months	No test within 12 months	
HSIL	21–59	Colposcopy	Colposcopy in 3 months	No test within 12 months	

152 \* no additional test between index and follow-up test

153

## 154 *HPV testing among women aged 21–29 years*

The HPV test was not recommended as a screening test in this age group. However, in the case of cervical pathology ASC-US among 21–24-year-old women and ASC-US or LSIL among 25–29-year-old women, HPV test was allowed. Thus, these age groups were analysed separately. The index date was the first HPV test between 01.01.2016–31.12.2019. Next, the preceding PAP test together with its result was identified. The period for the preceding PAP test was set 12 months before or 30 days after the index date.

## 162 Data analysis

163 To describe the overall sample, we calculated the annual rates of PAP tests, HPV tests and 164 colposcopies per 100 000 women together with 95% confidence intervals (95% CI) using the midyear population counts for the denominator. Repeated testing within 30 days was 165 166 considered duplicates and only the first record was included in the analysis. The threshold of 167 30 days was chosen to account for different testing and laboratory analysis pathways. The 168 differences in the number of tests between the two guideline periods were described using 169 absolute and relative change of rates. The p-values were calculated using a z-test of 170 proportions, and the statistical significance level was set at p < 0.05. When describing the adherence, under- and over-testing during the 3<sup>rd</sup> guideline period, ratios together with 95% CI 171 172 are presented. The analysis was performed using R v4.1.2.

173

## 174 **RESULTS**

## 175 The study cohort

176 During the study period, 72.6% of 21–65-year-old and 23.7% of 16–20-year-old women had

- 177 received at least one PAP test (Table 2).
- 178 **Table 2.** PAP tests, HPV tests, and colposcopies in 2012–2019 for 21–65-year-old (n = 47 570)
- and 16–20-year-old (n = 7404) women, in Estonia. The number of tests, women who received
- 180 at least one test and their proportion.

	Procedures (n)		Women received at least one procedure (n (%))	
Age:	16–20y	21–65y	16–20y	21–65y
PAP test	2 567	103 213	1 755 (23.7%)	34 530 (72.6%)
HPV test	236	10 177	206 (2.8%)	7 060 (14.8%)
Colposcopy	178	6 830	135 (1.8%)	3 972 (8.3%)

181

## **183** The effect of guidelines on the testing practices

During the  $3^{rd}$  guideline period (2016–2019) there was a statistically significant decline in the number of PAP tests and an increase in HPV tests in both age groups compared with the  $2^{nd}$ guideline version (P < 0.001) (Table S2). The decline in colposcopies during the  $3^{rd}$  period was present only among 16–20 years-old women (P < 0.01) (Table S2). The annual PAP testing, HPV testing and colposcopy rates per 100 000 women is presented in Figure 1.




Figure 1. The rate of women per 100 000 who received PAP tests, HPV tests or colposcopies
during 2<sup>nd</sup> and 3<sup>rd</sup> guideline versions (2012–2014 vs 2016–2019) in the age groups 16–20 years
(A) and 21–65 years (B).

193

189

# 194 Adherence to cervical cancer prevention and care continuum in 2015–2019

195 The adherence to guidelines after NILM was 22.7% (95% CI 20.4 - 24.8) among 21–29-year-

196 old and 20.5% (95% CI 19.4 - 21.5) among 30–59-year-old women (Table 3).

Table 3. The proportion of adherent, under- and over-tested women based on the PAP test
outcome among age groups 21–29 and 30–59 years.

	Ν	Adherent	Undertested	Over-tested
		% (95% CI)	% (95% CI)	% (95% CI)
21-29 years				
NILM	1373	22.7 (20.424.8)	25.1 (22.827.4)	17.6 (15.519.6)
ASC-US	295	38.7 (44.450.1)	25.7 (20.830.8)	11.9 (8.215.6)
LSIL	142	39.4 (31.447.8)	19.0 (12.625.5)	12.0 (6.617.3)
ASC-H	50	68.0 (55.180.1)	8.0 (0.515.5)	2.0 (-1.95.9)
HSIL	64	73.4 (62.684.3)	4.7 (-0.59.9)	-
30-59 years				
NILM	5768	20.5 (19.421.5)	27.0 (25.828.1)	17.1 (16.118.1)
ASC-US	975	49.0 (45.952.2)	21.9 (19.424.5)	9.5 (7.711.4)
LSIL	214	51.9 (45.258.6)	13.1 (8.617.6)	5.6 (2.58.7)
ASC-H	178	65.7 (58.872.7)	6.7 (3.110.4)	0.6 (-0.51.7)
HSIL	176	64.2 (57.171.3)	11.9 (7.116.7)	0.6 (-0.51.7)

200

201 Among 21–29-year-old women, 68.0% (95% CI 55.1 - 80.1) of women with ASC-H and 73.4% 202 (95% CI 62.6 - 84.3) with HSIL were adherent with the guidelines (Table 3). When looking at 203 a one-year period, the proportion of 30-59-year-old women receiving colposcopy was 80.0% 204 (95% CI 68.9 - 91.1) for ASC-H and 87.5% (95% CI 79.4 - 95.6) for HSIL (Figure 2). The proportion of women with no follow-up activity after ASC-H and HSIL was below 10% (Table 205 206 3). In the case of milder pathologies (ASC-US, LSIL) less than half of 21–29-year-old women 207 were adherent with the guidelines, while 25.7% (95% CI 20.8 - 30.8) of women with ASC-US 208 and 19.0% (95% CI 12.6 - 25.5) of women with LSIL did not receive any tests within 15 months 209 after the first corresponding pathology.







Figure 2. The time of colposcopy after ASC-H (A) and HSIL (B) by age group.

As for 30–59-year-old women, in the case of cervical pathology the adherence to guidelines 213 214 ranged from 49.0% (95% CI 45.9 - 52.2) for ASC-US to 65.7% (95% CI 58.8 - 72.7) for ASC-215 H (Table 3). The highest rate of undertested women with a cervical pathology was observed 216 for ASC-US (21.9%, 95% CI 19.4 - 24.5) and lowest for ASC-H (6.7%, 95% CI 3.1 - 10.4). 217 When looking at a one-year period, 76.4% (95% CI 70.2 - 82.6) of women with ASC-H and 218 72.2% (95% CI 65.5 - 78.8) with HSIL received a colposcopy (Figure 2). 219 As for the HPV testing among women aged 21-29 years there were 55.2% (95% CI 49.7 -220 60.8) of 21–24-year-old and 57.1% (95% CI 53.6 - 60.6) 25–29-year-old women who received 221 an HPV test without a preceding PAP test or the result of the preceding PAP test did not require 222 additional HPV test (Figure 3). The proportion of women whose HPV test was performed

- 223 according to the guidelines was 18.0% (95 CI 13.7 22.3) among 21–24-year-old and 26.6%
- 224 (95% CI 23.5 29.7) among 25–29-year-old women.



225

Figure 3. The distribution of 21–24 (A) and 25–29 (B) year-old women who had their first
HPV test between 2016–2019 based on the preceding PAP test.

## 229 **DISCUSSION**

230 The study extends the current literature on the adherence to cervical cancer screening 231 guidelines. Our findings indicate that the guidelines have an influence on the practice, and that 232 overall, the new guideline has been adopted by the practitioners. Still, there are some 233 shortcomings that need to be addressed. For example, the adherence rates of follow-up ranged 234 from 40–73% depending on the cervical pathology and age, while better follow-up care was 235 provided for women with high-grade pathology. A considerable proportion of women were 236 undertested and thus, did not receive an optimal protection against cervical cancer, while 237 overtesting was more prevalent among young women under 30. Our results give a good insight 238 into the quality of care and highlight aspects that need to be addressed to reduce the incidence 239 and mortality of cervical cancer.

After implementing the 3<sup>rd</sup> version of the cervical cancer screening guidelines, the number of PAP tests reduced and HPV tests increased. These trends in PAP tests in both age groups and HPV tests among 21–65-year-old women are consistent with previous studies [8,24,25]. Although some studies have suggested that increasing the testing interval can be a barrier to implementing the guidelines [6,9], this seems not to be the case in our study. It could be hypothesised that the relatively successful adoption of the new guideline can, at least partly, be attributable to the fact that the national gynaecologists society led the whole guideline development and dissemination process.

248 However, our study documented considerable over-testing. First, there was a significant increase in HPV testing among 16-20-year-old women during the 3<sup>rd</sup> guideline version 249 250 compared to the previous guideline. As HPV test is not recommended in this age group, this 251 trend can be classified as over-testing. This increase contradicts earlier studies conducted in the US where the number of HPV tests remained steady [25] or had a slight decline [25]. 252 253 Secondly, we observed a substantial over-testing among 21–29-year-old women where more 254 than half of HPV tests did not have a preceding PAP test result as recommended by the 255 guidelines. Thirdly, 12% of young women with ASC-US and LSIL and a fifth with NILM 256 received additional tests before the follow-up test recommended by the guidelines. Therefore, 257 the over-testing tends to be more prevalent among women under 30. Such surplus tests are not 258 only an inefficient use of healthcare resources, but they can cause stress and anxiety for women 259 [27] and negatively impact the reproductive health [10]. Moreover, as the low-grade cytologic 260 findings of young women tend to experience regression without any intervention [10,28], 261 caution is recommended in treating them [29]. It could be hypothesised that the increase in 262 HPV testing among young women is due to the guideline change as HPV test became the 263 primary screening test in the 3rd guideline and the recommended age range was just unnoticed 264 by the practitioners. Our findings suggests that more effort should be made to raise the 265 awareness of clinicians about the recommended testing and treatment pathways among young 266 women.

In accordance with the previous findings [12], our study indicates that women with high-gradecervical pathology had better follow-up care than low-grade pathology. This is reflected both

269 in the adherence rates as well as in the proportion of undertested women. The adherence rates 270 for high-grade cervical pathologies (ASC-H and HSIL) ranged in our study from 64% among 271 30–59-year-old with HSIL to 73% among 21–29-year-old with HSIL, which were lower than 272 previously reported in Canada [16] and higher than in the USA [29]. Whereas the adherence 273 rates for low-grade cervical pathologies in our study remained around 39% to 52%. However, 274 it should be highlighted, that despite having a better follow-up care in the case of high-grade 275 cervical pathology, almost a fifth of women with ASC-H and HSIL did not receive a 276 colposcopy within one year. When looking at the proportion of undertested women, the rates 277 of women without any follow-up test were a higher for women with low-grade cervical 278 pathology. Somewhat surprisingly, the lowest proportion of adherent women was in the case 279 of NILM, where only a fifth of women received their next PAP test as recommended in the 280 guidelines, while a quarter of women did not receive any additional testing within three and 281 half years. The proportion of adherent women with NILM in the current study is significantly 282 lower, and the proportion of undertested women higher compared to previously reported 283 [31,32]. Although irregular testing is better than no testing [33,34], the best protection against 284 cervical cancer is provided with regular testing and appropriate follow-up of cervical 285 pathologies [35,36]. Previously it has been shown that the main reason for under-screening is 286 the lack of knowledge of the guidelines among women [37]. Our results highlight the need to 287 improve the overall knowledge about cervical cancer and also an overall health literacy of 288 women. It has been pointed out that difficulty in understanding health information, lower 289 knowledge and worry about cervical cancer contribute to nonadherence to cervical cancer 290 screening [37,38]. In contrast, according to a meta-analysis, better health literacy is associated 291 with higher cervical cancer screening participation [40]. In addition, there are several 292 organizational factors that can support the participation in screening, such as receiving personal 293 reminders via different channels [41,42], or making the participation as convenient as possible.

It has been shown that long waiting lists, inappropriate appointment times, and distance from the clinic are some reasons for nonadherence [43]. Therefore, a multidisciplinary approach is needed where both the individual as well as healthcare system are addressed.

297 When interpreting our study results some limitations should be considered. First, there are some 298 completeness issues as 45% of the PAP test had no result reported in the EHR which hinders 299 the long-term analysis of testing patterns. Therefore, our study focused only on the first follow-300 up test rather than the whole treatment pathway. Second, the short timespan under observation 301 set some restrictions on evaluating the over- and undertesting, which could give a better 302 understanding of implementing the guidelines. Third, the study is also limited by the lack of 303 information on socio-demographic variables. At the same time, the strength of current study is 304 the close co-operation with Estonian Gynaecologists Society and clinical practitioners which 305 helped to identify several knowledge gaps in the implementation of cervical cancer prevention 306 guidelines. We addressed these gaps using real-world data by combining EHR and claims 307 database which store healthcare data for almost all Estonians, both insured and uninsured [23]. 308 The results of the study will be used to improve the implementation of the guidelines, plan 309 targeted interventions and nudge the policy makers and other stakeholders to support the 310 effective implementation of the guidelines to provide optimal treatment and care for the women 311 which in long-term should also result in the reduced incidence and mortality of cervical cancer.

312

#### 313 CONCLUSION

The study gave an important insight of the actual clinical practice and helped to identify several shortcomings in the implementation of cervical cancer prevention guidelines that need to be addressed. The practical input of the study will be used to provide better optimal treatment and better care for the women on national level. For some pathologies and age groups the adherence, overtesting or undertesting patterns seem to be similar internationally, indicating

- 319 universal trends to be present. However, there is a lack of studies monitoring the guideline
- 320 adherence for follow-up testing. Thus, more research is needed to reveal both unnecessary and
- 321 insufficient testing practices and take action against them.
- 322

323 Abbreviations

- 324 AIS adenocarcinoma in situ of the cervix
- 325 ASC-H atypical squamous cells cannot exclude HSIL
- 326 ASC-US atypical squamous cells of undetermined significance
- 327 EHR electronic health record
- 328 HSIL high-grade squamous intraepithelial lesions
- 329 LSIL atypical squamous cells of undetermined significance
- 330 NILM negative for intraepithelial lesion or malignancy
- 331 OMOP Observational Medical Outcomes Partnership
- 332

## 333 DECLARATIONS

- 334 Ethics approval and consent to participate
- 335 The study was approved by the Research Ethics Committee of the University of Tartu (300/T-
- 336 23) and the Estonian Committee on Bioethics and Human Research (1.1-12/653) and the
- 337 requirement for informed consent was waived.

338

- 339 Consent for publication
- 340 Not applicable.

342	Availability of data and materials
343	There are legal restrictions on sharing de-identified data. According to legislative regulation
344	and data protection law in Estonia, the authors cannot publicly release the data received from
345	the health data registries in Estonia.
346	
347	Competing interests
348	The authors declare that they have no competing interests.
349	
350	Funding
351	The research was carried out with the financial support of the Estonian Research Council grant
352	(PRG1844), the European Social Fund via the IT Academy programme, the European Regional
353	Development Fund through EXCITE Centre of Excellence (TK148) and OPTIMA project
354	(grant agreement No. 101034347) through IMI2 Joint Undertaking supported by European
355	Union's Horizon 2020 research and innovation programme and the European Federation of
356	Pharmaceutical Industries and Associations (EFPIA).
357	
358	Authors' contribution
359	All authors participated in the conceptualisation, planning, revision and editing process and
360	have approved the submitted version. In addition, data, the methodology was developed by
361	KM, MO, ST, AU, RK. The data cleaning, data analysis and visualisations were carried out by
362	MO, ST, MH, KM, MP. The initial draft was written by KM.
363	
364	Acknowledgements

365 Not applicable.

## 366 **References**

- 367 1. International Agency of Research on Cancer, WHO. Cancer today [Internet]. 2022 [cited
   368 2022 Feb 23]. Available from: https://gco.iarc.fr/today/
- 369 2. Global strategy to accelerate the elimination of cervical cancer as a public health problem.370 Geneva: World Health Organization; 2020.
- 371 3. Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, et al. The
  372 IARC Perspective on Cervical Cancer Screening. N Engl J Med. 2021;385:1908–18.
- 4. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of Cervical Cancer Screening in 57
  Countries: Low Average Levels and Large Inequalities. PLoS Med. 2008;5:e132.
- 5. Zhang W, Gao K, Fowkes FJI, Adeloye D, Rudan I, Song P, et al. Associated factors and
  global adherence of cervical cancer screening in 2019: a systematic analysis and modelling
  study. Glob Health. 2022;18:101.
- 6. Parekh N, Donohue JM, Men A, Corbelli J, Jarlenski M. Cervical Cancer Screening
  Guideline Adherence Before and After Guideline Changes in Pennsylvania Medicaid. Obstet
  Gynecol. 2017;129:66–75.
- 7. Franklin M, Webel A, Kaelber D, Evans J, Kelley C. Prevalence of Cervical Cancer
  Overscreening: Review of a Wellness Registry. CIN Comput Inform Nurs. 2020;38:459–65.
- 8. Qin J, Shahangian S, Saraiya M, Holt H, Gagnon M, Sawaya GF. Trends in the use of
  cervical cancer screening tests in a large medical claims database, United States, 2013–2019.
  Gynecol Oncol. 2021;163:378–84.
- 9. Perkins RB, Anderson BL, Sheinfeld Gorin S, Schulkin JA. Challenges in Cervical Cancer
  Prevention. Am J Prev Med. 2013;45:175–81.
- 10. Campaner AB, Fernandes GL. Cervical Cancer Screening of Adolescents and Young
  Women: Further Evidence Shows a Lack of Clinical Value. J Pediatr Adolesc Gynecol.
  2021;34:6–11.
- 391 11. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer:
  392 Systematic review and meta-analysis. Prev Med. 2007;45:93–106.
- 393 12. Singhal R, Rubenstein LV, Wang M, Lee ML, Raza A, Holschneider CH. Variations in
  394 Practice Guideline Adherence for Abnormal Cervical Cytology in a County Healthcare System.
  395 J Gen Intern Med. 2008;23:575–80.
- Jørgensen SF, Andersen B, Rebolj M, Njor SH. Gaps between recommendations and their
   implementation: A register-based study of follow-up after abnormalities in cervical cancer
   screening. Prev Med. 2021;146:106468.
- 14. Kupets R, Lu Y, Vicus D, Paszat L. Are There Flaws in the Follow-Up of Women With
  Low-Grade Cervical Dysplasia in Ontario? J Obstet Gynaecol Can. 2014;36:892–9.

- 401 15. Elit L, Krzyzanowska M, Saskin R, Barbera L, Razzaq A, Lofters A, et al.
  402 Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal
  403 results. Can Fam Physician. 2012;58:e22.
- 404 16. Elit L, Saskin R, Raut R, Elliott L, Murphy J, Marrett L. Sociodemographic factors
  405 associated with cervical cancer screening coverage and follow-up of high grade abnormal
  406 results in a population-based cohort. Gynecol Oncol. 2013;128:95–100.
- 407 17. Ioannidis JPA. Why Most Clinical Research Is Not Useful. PLOS Med. 2016;13:e1002049.
- 408 18. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research409 evidence. The Lancet. 2009;374:86–9.
- 410 19. Gleadhill C, Williams CM, Kamper SJ, Bolsewicz K, Delbridge A, Mahon B, et al.
  411 Meaningful coproduction with clinicians: establishing a practice-based research network with
  412 physiotherapists in regional Australia. Health Res Policy Syst. 2023;21:38.
- 20. Graham ID, McCutcheon C, Kothari A. Exploring the frontiers of research co-production:
  the Integrated Knowledge Translation Research Network concept papers. Health Res Policy
  Syst. 2019;17:88, s12961-019-0501-7.
- 416 21. OMOP Common Data Model, v5.3 [Internet]. 2023. Available from:
  417 https://ohdsi.github.io/CommonDataModel/cdm53.html
- 22. Oja M, Tamm S, Mooses K, Pajusalu M, Talvik H-A, Ott A, et al. Transforming Estonian
  health data to the Observational Medical Outcomes Partnership (OMOP) Common Data
  Model: lessons learned. medRxiv. 2023;2023.02.16.23285697.
- 421 23. Nayar R, Wilbur D. The Bethesda System for Reporting Cervical Cytology. Definitions,
  422 Criteria, and Explanatory Notes. Third edition. Springer Cham; 2015.
- 423 24. Hirth JM, Tan A, Wilkinson GS, Berenson AB. Compliance with cervical cancer screening
  424 and human papillomavirus testing guidelines among insured young women. Am J Obstet
  425 Gynecol. 2013;209:200.e1-200.e7.
- 426 25. MacLaughlin KL, Jacobson RM, Radecki Breitkopf C, Wilson PM, Jacobson DJ, Fan C,
  427 et al. Trends Over Time in Pap and Pap-HPV Cotesting for Cervical Cancer Screening. J
  428 Womens Health 2002. 2019/01/07 ed. 2019;28:244–9.
- 429 26. McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for
  430 human papillomavirus in routine cervical screening: examination of psychosocial impact.
  431 BJOG Int J Obstet Gynaecol. 2004;111:1437–43.
- 432 27. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical dysplasia:
  433 histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol. 2007;197:141.e1434 141.e6.
- 435 28. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E.
- 436 Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical
- 437 lesions: systematic review and meta-analysis. The Lancet. 2006;367:489–98.

- 438 29. Tosteson ANA, Beaber EF, Tiro J, Kim J, McCarthy AM, Quinn VP, et al. Variation in
  439 Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer
  440 Screening within the PROSPR Consortium. J Gen Intern Med. 2016;31:372–9.
- 30. de la Motte Rouge T, Touboul C, Lhomel C, Rouprêt M, Morère J-F. Factors associated
  with compliance to cervical cancer screening in France: The EDIFICE 6 survey. Gynecol
  Oncol. 2021;160:112–7.
- 444 31. Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, et al.
  445 Adherence patterns to extended cervical screening intervals in women undergoing human
  446 papillomavirus (HPV) and cytology cotesting. Prev Med. 2018;109:44–50.
- 447 32. Pedersen K, Burger EA, Campbell S, Nygård M, Aas E, Lönnberg S. Advancing the
  448 evaluation of cervical cancer screening: development and application of a longitudinal
  449 adherence metric. Eur J Public Health. 2017;27:1089–94.
- 33. Dugué P-A, Lynge E, Rebolj M. Mortality of non-participants in cervical screening:
  Register-based cohort study: Mortality of non-participants in cervical screening. Int J Cancer.
  2014;134:2674–82.
- 453 34. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines
   454 for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document.
- 455 Ann Oncol. 2010;21:448–58.
- 456 35. Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer
  457 mortality: estimation using stage-specific results from a nested case–control study. Br J Cancer.
  458 2016;115:1140–6.
- 36. Suk R, Hong Y-R, Rajan SS, Xie Z, Zhu Y, Spencer JC. Assessment of US Preventive
  Services Task Force Guideline–Concordant Cervical Cancer Screening Rates and Reasons for
  Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005
  to 2019. JAMA Netw Open. 2022;5:e2143582.
- 463 37. Galvin AM, Garg A, Matthes S, Thompson EL. Utilizing a Multidimensional Health
  464 Literacy Framework to Assess Cervical Cancer Screening Nonadherence. Health Educ Behav.
  465 2021;48:710–8.
- 38. Grigore M, Popovici R, Pristavu A, Grigore AM, Matei M, Gafitanu D. Perception and use
  of Pap smear screening among rural and urban women in Romania. Eur J Public Health.
  2017;27:1084–8.
- 39. Baccolini V, Isonne C, Salerno C, Giffi M, Migliara G, Mazzalai E, et al. The association
  between adherence to cancer screening programs and health literacy: A systematic review and
  meta-analysis. Prev Med. 2022;155:106927.
- 40. Ruco A, Dossa F, Tinmouth J, Llovet D, Jacobson J, Kishibe T, et al. Social Media and
  mHealth Technology for Cancer Screening: Systematic Review and Meta-analysis. J Med
  Internet Res. 2021;23:e26759.
- 475 41. Schliemann D, Tan MM, Hoe WMK, Mohan D, Taib NA, Donnelly M, et al. mHealth
- Interventions to Improve Cancer Screening and Early Detection: Scoping Review of Reviews.
  J Med Internet Res. 2022;24:e36316.

- 478 42. Kivistik A, Lang K, Baili P, Anttila A, Veerus P. Women's knowledge about cervical 479 cancer risk factors, screening, and reasons for non-participation in cervical cancer screening
- 480 programme in Estonia. BMC Womens Health. 2011;11:43–43.